Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Isomorphic Labs
AddedMay 14, 2026
UpdatedJul 15, 2026
Isomorphic Labs

Isomorphic Labs

Series B

Isomorphic Labs is an Alphabet-backed biotechnology company pioneering AI-driven drug discovery with a unified drug design engine.

HQ
London, GB
Founded
2021
Overview
Analysis
Compare
Fundraising
Employees
News
Website

Isomorphic Labs Limited was founded by Sir Demis Hassabis in February 2021 as a spin-off from Google DeepMind, a subsidiary of Alphabet Inc. Headquartered in London with offices in Lausanne and Cambridge, Massachusetts, the company is advancing drug discovery through an AI-first approach.

The company Drug Design Engine builds on the Nobel-winning AlphaFold system to predict biomolecular structures and binding affinities with unprecedented accuracy, and has raised approximately $2.7 billion in funding with strategic collaborations at Novartis, Eli Lilly, and Johnson \u0026 Johnson.

Isomorphic Labs - Products & Services

  • Drug Design Engine logo

    Drug Design Engine

    Isomorphic Labs' Drug Design Engine builds on AlphaFold to predict biomolecular structures for drug discovery.

    Competing Products

    Insilico Medicine logo
    Inherent logo

Isomorphic Labs - Similar Companies

Numerion Labs logo

Numerion Labs

Verge Genomics logo

Verge Genomics

Relay Therapeutics logo

Relay Therapeutics

Schrödinger logo

Schrödinger

Insitro logo

Insitro

Recursion Pharmaceuticals logo

Recursion Pharmaceuticals

Insilico Medicine logo

Insilico Medicine

insilico.com

Inherent logo

Inherent

inherentlabs.ai

Diffuse Bio logo

Diffuse Bio

diffuse.bio

Atomic AI logo

Atomic AI

atomic.ai

Genesis Therapeutics logo

Genesis Therapeutics

Biosim logo

Biosim

Google DeepMind logo

Google DeepMind

deepmind.google

Atommap logo

Atommap

1910 logo

1910

1910genetics.com

Isomorphic Labs - Quick Facts

Who are Isomorphic Labs' competitors?

Companies similar to Isomorphic Labs include Insilico Medicine, Inherent, Numerion Labs and Verge Genomics.

When was Isomorphic Labs founded?

Isomorphic Labs was founded in 2021.

Where is Isomorphic Labs' headquarters located?

Isomorphic Labs' headquarters is located in London, GB.

When was Isomorphic Labs' last funding round?

Isomorphic Labs' most recent funding round was for $2.1B (USD) in May 2026.

How much has Isomorphic Labs raised to-date?

As of May 12, 2026, Isomorphic Labs has raised a total of $2.8B (USD).

Isomorphic Labs - Classification

Industry
  • Biotechnology
  • Drug Discovery
Ownership
  • Venture-backed private company
Technology
  • Machine Learning
Geographic Exposure
  • United Kingdom
Model
  • AI Lab
Revenue
  • Licensing
Customer
  • Enterprise
Tags
  • AI-native science
  • Biotechnology